PROmotion of FLU Vaccine Uptake in the Emergency Department

Status Completed

Clinical Trial Summary

The goal of this research is to increase influenza vaccine acceptance and uptake in vulnerable populations whose primary (and often only) health care access occurs in emergency departments (ED Usual Source of Care Patients). Toward this goal, the investigators will conduct one on one interviews and focus groups with ED Usual Source of Care Patients and community partners and produce trusted messaging informational platforms (PROmotion of FLU VA(X)ccination in the Emergency Department - PROFLUVAXED) that will address barriers to flu vaccination, especially vaccine hesitancy. The investigators will then conduct a cluster-randomized, controlled trial of PROFLUVAXED platforms in six EDs to determine whether their implementation is associated with greater flu vaccine acceptance and uptake in ED Usual Source of Care Patients.

Clinical Trial Description

Specific Aim I: To determine whether implementation of influenza vaccine trusted messaging platforms is associated with increased influenza vaccine uptake in unvaccinated ED patients. At six EDs (Zuckerberg San Francisco General, UCSF Parnassus Medical Center [San Francisco, CA], Thomas Jefferson University Hospital [Philadelphia, PA], Ben Taub Hospital [Houston, TX], Harborview Medical Center [Seattle, WA], and Duke University Medical Center [Durham, NC]), investigators will conduct a cluster-randomized controlled trial of implementation of PROFLUVAXED trusted messaging platforms, with influenza vaccine uptake in the ED as the primary outcome. Hypothesis: Implementation of PROFLUVAXED trusted messaging platforms in EDs will be associated with increased influenza vaccine uptake in unvaccinated ED patients. Specific Aim II: To determine whether implementation of influenza vaccine trusted messaging platforms in EDs is associated with increased influenza vaccine acceptance in unvaccinated ED patients. For this specific aim influenza vaccine acceptance in the ED assessed via ED survey will be the primary outcome. Hypothesis: Implementation of PROFLUVAXED trusted messaging platforms in EDs will be associated with increased influenza vaccine acceptance in unvaccinated ED patients. Specific Aim III: To determine whether implementation of a protocol in which ED patients are asked whether they will accept an influenza vaccine in the ED (and notifying ED providers when they say they will accept it) is associated with increased influenza vaccine uptake in unvaccinated ED patients. Hypothesis: Implementation of an ED protocol in which patients are asked whether they will accept an influenza vaccine (and notifying ED providers when they say they will accept it) will be associated with increased influenza vaccine uptake in unvaccinated ED patients. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT05836818
Study type	Interventional
Source	University of California, San Francisco
Contact
Status	Completed
Phase	N/A
Start date	October 1, 2022
Completion date	March 30, 2023

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT05509270` - Efficacy of Communication Modalities for Promoting Flu Shots	N/A
Recruiting	`NCT05479370` - Immunogenicity Trial of 3 Influenza Vaccines	Phase 3
Completed	`NCT03637036` - An Improvement Project Around Staffs' Influenza Vaccine Uptake	N/A
Completed	`NCT01942824` - Adult Influenza Vaccination Text Message Reminders	N/A
Completed	`NCT01009645` - The Effect of Fact Versus Myth Messages on Receipt of Influenza Vaccination	N/A
Completed	`NCT05783713` - Evaluation of the Effectiveness of a Flu Vaccination Campaign for Healthcare Workers of a Teaching Hospital: a Pre-post Study
Recruiting	`NCT03346772` - Study of Immune Responses to Influenza Vaccination	Phase 4
Completed	`NCT03104790` - Assessment of Viral Shedding in Children Previously in Receipt of Multiple Doses of Live Attenuated Influenza Vaccine (LAIV) Compared to Influenza Vaccine-naïve Controls	Phase 4
Completed	`NCT04188483` - Effect of Selenium Supplementation on Influenza Vaccination	N/A
Completed	`NCT05785078` - Evaluation of a Flu Vaccination Program Directed at Pregnant Women Assisted at a Research Hospital in Italy.
Completed	`NCT04568785` - Effectiveness of a Brief Intervention for Acceptance of Influenza Vaccine in the Primary Care Setting	N/A
Completed	`NCT03167593` - Effects of Lactobacillus Coryniformis CECT5711 on Immune Response to Influenza Vaccination in Adults Over 65.	Phase 2
Completed	`NCT01233804` - Opting In vs Opting Out	N/A
Completed	`NCT04494581` - GriCoVax Study in 4 Maternity Wards in the Ile-de-France Region
Recruiting	`NCT04367883` - Influenza Vaccination, ACEI and ARB in the Evolution of SARS-CoV2 Infection
Completed	`NCT06300242` - Incentives for Influenza Vaccination	N/A

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

PROmotion of FLU Vaccine Uptake in the Emergency Department - PROFLUVAXED — PROFLUVAXED

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms